Synergistic Effect of Intravenous Lidocaine on Anesthetic Induction and Emergence in Patients Undergoing Laparoscopic Cholecystectomy or Gynecological Surgery
Cholecystectomy, LaparoscopicGynecologic Surgical ProceduresAnesthesia and Procedure Related Time Intervals
Investigational drug(s) / intervention(s)
Normal Saline (0.9% NaCl)LidocaineLidocaine Bolus + Infusion
Normal Saline (0.9% NaCl): Participants in the control group received a single intravenous injection of 0.9% normal saline at induction of anesthesia.
Lidocaine: Participants in this group received a single intravenous bolus of lidocaine (1.5 mg/kg) at anesthesia induction. No additional lidocaine was administered thereafter.
Lidocaine Bolus + Infusion: Participants in this group received a bolus of lidocaine (1.5 mg/kg) at induction followed by continuous intravenous infusion of lidocaine (2 mg/kg/h) until the end of surgery.
Study summary
This study aims to evaluate the effect of intravenous lidocaine on consciousness changes during anesthesia in patients undergoing laparoscopic cholecystectomy or gynecologic surgery. A total of 150 patients will be randomly assigned to one of three groups: a single-dose lidocaine group, a continuous-infusion group, or a placebo group. All patients will receive standard anesthesia care, and the study will monitor brain activity using EEG-based PSi values to measure anesthesia induction time, recovery time, and changes in consciousness. The goal is to determine whether lidocaine can reduce the amount of anesthetic used, shorten the time to fall asleep, and promote faster awakening after surgery. The results may help improve anesthesia safety and enhance recovery in surgical patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18 to 75 years.
* ASA physical status I-III.
* Scheduled for elective laparoscopic cholecystectomy, laparoscopic
* hysterectomy, or laparoscopic ovarian cystectomy.
* Expected surgical duration \< 120 minutes.
* Preoperative normal cognitive function (MoCA \> 26).
* Able and willing to provide written informed consent.
Exclusion Criteria:
* Known allergy to lidocaine or other amide-type local anesthetics.
* History of severe arrhythmias, heart failure (NYHA class III or higher), or epilepsy.
* Central nervous system disorders (e.g., stroke, brain trauma, seizure disorders) or psychiatric illness.
* Severe hepatic or renal dysfunction (ALT/AST \> 2× ULN, or eGFR \< 60 ml/min/1.73 m²).
* Currently taking medications that affect CNS function (e.g., benzodiazepines, antidepressants, antiepileptics).
* Pregnant or breastfeeding women.
* History of drug or alcohol dependence.
* BMI \> 30 kg/m² or \< 18 kg/m².
* Inability to understand study procedures or refusal to sign informed consent.
Primary outcome measure(s)
Time to emergence from general anesthesia — Immediately after anesthesia discontinuation (Day 0) Measured as the time interval (in seconds) from discontinuation of anesthetics to eye opening on verbal command.
Time to loss of consciousness — During anesthesia induction on Day 0 Measured as the time (in seconds) from the beginning of propofol administration to loss of response to verbal command and eyelash reflex.
Trial sites (1)
Facility
City
Region
Status
General Hospital of Ningxia Medical University
Yinchuan
Ningxia
More General Hospital of Ningxia Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.